SeptRx, a Fremont, CA-based cardiovascular medical device company that is developing a platform for the percutaneous transcatheter closure of a heart defect known as patent foramen ovale (PFO), has raised $2.7m in a Series A financing.
The round was led by Nitinol Devices & Components Inc.
The company intends to use the funds to obtain CE mark registration for its medical device, the SeptRx® IPO, or Intrapocket PFO Occluder, designed to close the heart defect and lower the risk of stroke.
The device has already completed a first-in-human (FIH) clinical trial. A larger European clinical trial, whose data will be used to apply for CE marking, is expected to start soon at two investigation sites in Frankfurt, Germany, and Massy, France.
SeptRx is led by President and CEO Scott Russell.